Cellectis SA (CLLS)
3.00
-0.04
(-1.31%)
USD |
NASDAQ |
May 17, 16:00
3.00
0.00 (0.00%)
After-Hours: 20:00
Cellectis Research and Development Expense (Quarterly): 25.53M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 25.53M |
| September 30, 2023 | 18.89M |
| June 30, 2023 | 22.14M |
| March 31, 2023 | 21.08M |
| December 31, 2022 | 21.43M |
| September 30, 2022 | 23.84M |
| June 30, 2022 | 25.63M |
| March 31, 2022 | 26.60M |
| December 31, 2021 | 21.18M |
| September 30, 2021 | 34.32M |
| June 30, 2021 | 31.15M |
| March 31, 2021 | 31.00M |
| December 31, 2020 | 13.45M |
| September 30, 2020 | 20.10M |
| June 30, 2020 | 22.86M |
| March 31, 2020 | 20.72M |
| December 31, 2019 | 30.44M |
| September 30, 2019 | 21.60M |
| Date | Value |
|---|---|
| June 30, 2019 | 25.42M |
| March 31, 2019 | 14.51M |
| December 31, 2018 | 21.40M |
| September 30, 2018 | 18.69M |
| June 30, 2018 | 18.04M |
| March 31, 2018 | 18.40M |
| December 31, 2017 | 20.70M |
| September 30, 2017 | 20.29M |
| June 30, 2017 | 18.61M |
| March 31, 2017 | 19.58M |
| December 31, 2016 | 20.19M |
| September 30, 2016 | 15.43M |
| June 30, 2016 | 21.72M |
| March 31, 2016 | 21.39M |
| December 31, 2015 | 17.22M |
| September 30, 2015 | 18.18M |
| June 30, 2015 | 14.34M |
| March 31, 2015 | 8.053M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
13.45M
Minimum
Dec 2020
34.32M
Maximum
Sep 2021
24.07M
Average
22.86M
Median
Jun 2020
Research and Development Expense (Quarterly) Benchmarks
| DBV Technologies SA | 21.40M |
| Biophytis SA | -- |
| Genfit SA | -- |
| Edap TMS SA | 2.370M |
| Adaptimmune Therapeutics PLC | 35.21M |